Main Achievements

In recent years, EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST). The following compounds were investigated within this group (STBSG):

Multicentre trials, with large patient numbers to influence clinical practice and address important research topics, evaluated the role of adjuvant chemotherapy in soft tissue sarcoma patients (more information) as well as the role of single-agent doxorubicin versus the combination of doxorubicin plus ifosfamide in advanced and/or metastatic STS patients (more information).

Related Projects

  • euroSARC: the synovial sarcoma project EuroJOSS (link) EuroEwing 2012 & rEECurr (link) Joint Action on Rare Cancers
  • European Reference Networks (ERN) for rare solid tumours (EURACAN) (link ).
  • EORTC-1637 (lms retrospective): retrospective evaluation of first-line treatment for advanced, metastatic or unresectable leiomyosarcomas.
    (project leader: lorenzo d’ambrosio)
    Status: database open
    This is a retrospective research project (rp) to evaluate the activity of doxorubicin as monotherapy as well as in combination with ifosfamide or dacarbazine as first-line treatment for leiomyosarcoma, pleomorphic leiomyosarcoma and undifferentiated sarcoma with smooth muscle differentiation, to potentially guide the design of a prospective randomized study.
    As of today, we have already into our database.
    Please be noted that we are planning to close the database by the end of march.
  • EORTC-1647 (angio. retrospective): retrospective evaluation of adjuvant chemotherapy in angiosarcoma.
    (project leader: robin jones)
    Research project approved: 23 aug. 2016
    The primary objective of the study will be to evaluate the activity of adjuvant chemotherapy in angiosarcoma patients and to potentially guide the design of a prospective randomized study.
    Several sites (around 41) from the STBSG are planning to contribute patient data from their clinical practice.

Research Group

Group documents
  • Chair

    Alessandro Gronchi

    Fondazione IRCCS Istituto Nazionale dei Tumori

    Milano, Italy

  • Secretary

    Bernd Kasper

    Mannheim University Medical Center

    Mannheim, Germany

  • Treasurer

    Ian Judson

    The Royal Marsden Hospital

    London, United Kingdom

Committee

  • E. Wardelmann - Muenster , DE

    Chair Pathology

    Gerhard Domagk Institute of Pathology - University Hospital Muenster

  • R. Haas - Amsterdam, NL

    Chair Local Treatment

    The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

  • A. Le Cesne - Villejuif, FR

    Chair Systemic Treatment

    Gustave Roussy

  • S. Bauer - Essen, DE

    Chair Translational Research

    Universitaetsklinikum - Essen

  • C. Messiou - London , GB

    Chair Imaging Subcommittee

    Royal Marsden Hospital

  • C. Honoré - Villejuif, FR

    Young Oncologists

    Gustave Roussy

  • W. van den Houdt - London , GB

    Young Oncologists

    Royal Marsden Hospital

  • I. Desar - Nijmegen , NL

    Young Oncologists

    Radboud University Medical Center Nijmegen

  • N. Hindi - Sevilla, ES

    Young Oncologists

    Virgen del Rocio University Hospital